Prognostic significance of reverse transcriptase-polymerase chain reaction-negative sentinel nodes in malignant melanoma

Diego Ribuffo, Angela Gradilone, Marco Vonella, Stefano Chiummariello, Emanuele Cigna, Nickolaos Haliassos, Rita Massa, Ida Silvestri, Stefano Calvieri, Luigi Frati, Anna Maria Aglianò, Nicolò Scuderi

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Background: Polymerase chain reaction (PCR) is a molecular biology technique that can detect a single metastatic cell in 106 to 10 7 normal cells. Its use has been proposed as an additional new method for the detection of malignant melanoma nodal metastases in the sentinel lymph node (SLN) to improve the detection rate guaranteed so far by standard histology (hematoxylin and eosin; H&E) and immunohistochemistry (IHC). Methods: Since October 1995, 137 patients with primary cutaneous melanoma (Breslow thickness, .75-4 mm) have undergone surgery for selective lymphadenectomy. To identify the SLNs, every patient had preoperative lymphoscintigraphy and a vital dye perilesional injection, followed by a gamma probe-guided operation. Results: In 134 patients at least one SLN was detected, with a detection rate of 98%. Every SLN was examined by H&E and IHC (S-100 antigen and HMB-45 protein). The messenger RNA codifying for tyrosinase and MART-1 (melanoma antigen recognized by T cells) was used as the target sequence for the reverse transcriptase (RT)-PCR. The results showed 11% positive SLNs with IHC and H&E examination and 63% with RT-PCR. No recurrence was noted at follow-up in the group with RT-PCR-negative nodes (absence of false-negative cases). Conclusions: In our experience, RT-PCR SLN negativity is achieving a very favorable prognostic significance. However, RT-PCR positivity is still to be evaluated. Furthermore, results obtained with this method have been shown so far to be independent of Breslow's tumor thickness.

Original languageEnglish
Pages (from-to)396-402
Number of pages7
JournalAnnals of Surgical Oncology
Volume10
Issue number4
DOIs
Publication statusPublished - 2003

Fingerprint

Reverse Transcriptase Polymerase Chain Reaction
Melanoma
Immunohistochemistry
MART-1 Antigen
Melanoma-Specific Antigens
Lymphoscintigraphy
Monophenol Monooxygenase
S100 Proteins
Hematoxylin
Eosine Yellowish-(YS)
Lymph Node Excision
Molecular Biology
Histology
Coloring Agents
cyhalothrin
Neoplasm Metastasis
T-Lymphocytes
Recurrence
Polymerase Chain Reaction
Messenger RNA

Keywords

  • MART-1
  • Melanoma
  • Polymerase chain reaction
  • Sentinel lymph node
  • Tyrosinase

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Ribuffo, D., Gradilone, A., Vonella, M., Chiummariello, S., Cigna, E., Haliassos, N., ... Scuderi, N. (2003). Prognostic significance of reverse transcriptase-polymerase chain reaction-negative sentinel nodes in malignant melanoma. Annals of Surgical Oncology, 10(4), 396-402. https://doi.org/10.1245/ASO.2003.06.006

Prognostic significance of reverse transcriptase-polymerase chain reaction-negative sentinel nodes in malignant melanoma. / Ribuffo, Diego; Gradilone, Angela; Vonella, Marco; Chiummariello, Stefano; Cigna, Emanuele; Haliassos, Nickolaos; Massa, Rita; Silvestri, Ida; Calvieri, Stefano; Frati, Luigi; Aglianò, Anna Maria; Scuderi, Nicolò.

In: Annals of Surgical Oncology, Vol. 10, No. 4, 2003, p. 396-402.

Research output: Contribution to journalArticle

Ribuffo, D, Gradilone, A, Vonella, M, Chiummariello, S, Cigna, E, Haliassos, N, Massa, R, Silvestri, I, Calvieri, S, Frati, L, Aglianò, AM & Scuderi, N 2003, 'Prognostic significance of reverse transcriptase-polymerase chain reaction-negative sentinel nodes in malignant melanoma', Annals of Surgical Oncology, vol. 10, no. 4, pp. 396-402. https://doi.org/10.1245/ASO.2003.06.006
Ribuffo, Diego ; Gradilone, Angela ; Vonella, Marco ; Chiummariello, Stefano ; Cigna, Emanuele ; Haliassos, Nickolaos ; Massa, Rita ; Silvestri, Ida ; Calvieri, Stefano ; Frati, Luigi ; Aglianò, Anna Maria ; Scuderi, Nicolò. / Prognostic significance of reverse transcriptase-polymerase chain reaction-negative sentinel nodes in malignant melanoma. In: Annals of Surgical Oncology. 2003 ; Vol. 10, No. 4. pp. 396-402.
@article{6b97c6e73b4a416c8ecb7bcc3b9cb538,
title = "Prognostic significance of reverse transcriptase-polymerase chain reaction-negative sentinel nodes in malignant melanoma",
abstract = "Background: Polymerase chain reaction (PCR) is a molecular biology technique that can detect a single metastatic cell in 106 to 10 7 normal cells. Its use has been proposed as an additional new method for the detection of malignant melanoma nodal metastases in the sentinel lymph node (SLN) to improve the detection rate guaranteed so far by standard histology (hematoxylin and eosin; H&E) and immunohistochemistry (IHC). Methods: Since October 1995, 137 patients with primary cutaneous melanoma (Breslow thickness, .75-4 mm) have undergone surgery for selective lymphadenectomy. To identify the SLNs, every patient had preoperative lymphoscintigraphy and a vital dye perilesional injection, followed by a gamma probe-guided operation. Results: In 134 patients at least one SLN was detected, with a detection rate of 98{\%}. Every SLN was examined by H&E and IHC (S-100 antigen and HMB-45 protein). The messenger RNA codifying for tyrosinase and MART-1 (melanoma antigen recognized by T cells) was used as the target sequence for the reverse transcriptase (RT)-PCR. The results showed 11{\%} positive SLNs with IHC and H&E examination and 63{\%} with RT-PCR. No recurrence was noted at follow-up in the group with RT-PCR-negative nodes (absence of false-negative cases). Conclusions: In our experience, RT-PCR SLN negativity is achieving a very favorable prognostic significance. However, RT-PCR positivity is still to be evaluated. Furthermore, results obtained with this method have been shown so far to be independent of Breslow's tumor thickness.",
keywords = "MART-1, Melanoma, Polymerase chain reaction, Sentinel lymph node, Tyrosinase",
author = "Diego Ribuffo and Angela Gradilone and Marco Vonella and Stefano Chiummariello and Emanuele Cigna and Nickolaos Haliassos and Rita Massa and Ida Silvestri and Stefano Calvieri and Luigi Frati and Aglian{\`o}, {Anna Maria} and Nicol{\`o} Scuderi",
year = "2003",
doi = "10.1245/ASO.2003.06.006",
language = "English",
volume = "10",
pages = "396--402",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York LLC",
number = "4",

}

TY - JOUR

T1 - Prognostic significance of reverse transcriptase-polymerase chain reaction-negative sentinel nodes in malignant melanoma

AU - Ribuffo, Diego

AU - Gradilone, Angela

AU - Vonella, Marco

AU - Chiummariello, Stefano

AU - Cigna, Emanuele

AU - Haliassos, Nickolaos

AU - Massa, Rita

AU - Silvestri, Ida

AU - Calvieri, Stefano

AU - Frati, Luigi

AU - Aglianò, Anna Maria

AU - Scuderi, Nicolò

PY - 2003

Y1 - 2003

N2 - Background: Polymerase chain reaction (PCR) is a molecular biology technique that can detect a single metastatic cell in 106 to 10 7 normal cells. Its use has been proposed as an additional new method for the detection of malignant melanoma nodal metastases in the sentinel lymph node (SLN) to improve the detection rate guaranteed so far by standard histology (hematoxylin and eosin; H&E) and immunohistochemistry (IHC). Methods: Since October 1995, 137 patients with primary cutaneous melanoma (Breslow thickness, .75-4 mm) have undergone surgery for selective lymphadenectomy. To identify the SLNs, every patient had preoperative lymphoscintigraphy and a vital dye perilesional injection, followed by a gamma probe-guided operation. Results: In 134 patients at least one SLN was detected, with a detection rate of 98%. Every SLN was examined by H&E and IHC (S-100 antigen and HMB-45 protein). The messenger RNA codifying for tyrosinase and MART-1 (melanoma antigen recognized by T cells) was used as the target sequence for the reverse transcriptase (RT)-PCR. The results showed 11% positive SLNs with IHC and H&E examination and 63% with RT-PCR. No recurrence was noted at follow-up in the group with RT-PCR-negative nodes (absence of false-negative cases). Conclusions: In our experience, RT-PCR SLN negativity is achieving a very favorable prognostic significance. However, RT-PCR positivity is still to be evaluated. Furthermore, results obtained with this method have been shown so far to be independent of Breslow's tumor thickness.

AB - Background: Polymerase chain reaction (PCR) is a molecular biology technique that can detect a single metastatic cell in 106 to 10 7 normal cells. Its use has been proposed as an additional new method for the detection of malignant melanoma nodal metastases in the sentinel lymph node (SLN) to improve the detection rate guaranteed so far by standard histology (hematoxylin and eosin; H&E) and immunohistochemistry (IHC). Methods: Since October 1995, 137 patients with primary cutaneous melanoma (Breslow thickness, .75-4 mm) have undergone surgery for selective lymphadenectomy. To identify the SLNs, every patient had preoperative lymphoscintigraphy and a vital dye perilesional injection, followed by a gamma probe-guided operation. Results: In 134 patients at least one SLN was detected, with a detection rate of 98%. Every SLN was examined by H&E and IHC (S-100 antigen and HMB-45 protein). The messenger RNA codifying for tyrosinase and MART-1 (melanoma antigen recognized by T cells) was used as the target sequence for the reverse transcriptase (RT)-PCR. The results showed 11% positive SLNs with IHC and H&E examination and 63% with RT-PCR. No recurrence was noted at follow-up in the group with RT-PCR-negative nodes (absence of false-negative cases). Conclusions: In our experience, RT-PCR SLN negativity is achieving a very favorable prognostic significance. However, RT-PCR positivity is still to be evaluated. Furthermore, results obtained with this method have been shown so far to be independent of Breslow's tumor thickness.

KW - MART-1

KW - Melanoma

KW - Polymerase chain reaction

KW - Sentinel lymph node

KW - Tyrosinase

UR - http://www.scopus.com/inward/record.url?scp=0043163401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0043163401&partnerID=8YFLogxK

U2 - 10.1245/ASO.2003.06.006

DO - 10.1245/ASO.2003.06.006

M3 - Article

C2 - 12734088

AN - SCOPUS:0043163401

VL - 10

SP - 396

EP - 402

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 4

ER -